Abiopharma

🔍 Chen Yun-Lung (Executive)

Company: AMBARELLA INC (AMBA)

Report Date: 2026-03-17

Detailed Transactions and Holdings:

• Acquired 4,651 shares of Ordinary Shares (Direct)
  Date: 2026-03-17 | Code: M | equity_swap_involved: 0 | shares_owned_after: 73,522.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 2,849 shares of Ordinary Shares (Direct)
  Date: 2026-03-18 | Code: A | equity_swap_involved: 0 | shares_owned_after: 76,371.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 4,651 shares of Performance Stock Units (Derivative)
  Date: 2026-03-17 | Code: M | Expires: 2026-03-15 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F3, F3

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of Ambarella, Inc. Ordinary Shares.
• F2: Represents an award of fully-vested restricted stock units (RSUs) issued to reporting person as payment of reporting person's annual bonus under the company's previously established Fiscal Year 2026 Annual Bonus Plan. Each restricted stock unit represents a contingent right to receive one Ordinary Share.
• F3: On April 3, 2023, reporting person was granted a performance-based RSU award covering a target number of ordinary shares (the "Target RSU Number"). Pursuant to time-based vesting requirements, the award would vest in full on March 15, 2026. In addition, the number of shares subject to the award could be decreased by up to 100% or increased by up to 150% of the Target RSU Number, based on attainment of specified levels of the Company's total stockholder return and revenue growth over the period of February 1, 2023 through January 31, 2026 (the "TSR Period"). As a result of the Company's performance over the TSR Period, the number of shares that vested was 100% of the Target RSU Number.